---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-036895"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2021-07-16T23:59:59+00:00"
generated_at: "2026-06-30T04:44:46.007475+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Enanta CMO Nathalie Adda to retire Feb 28, 2022; consulting deal signed

## Summary
- Nathalie Adda, MD, SVP and CMO, announced retirement effective February 28, 2022.
- Enanta entered a consulting agreement for up to 3 months post-retirement at $450/hour for up to 70 hours/month.
- Existing stock options and restricted stock units will continue to vest during the consulting term.

## SEC filing metadata
- accession: 0001564590-21-036895
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2021-07-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000156459021036895/0001564590-21-036895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000156459021036895/enta-8k_20210714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-036895
- JSON: https://secwatch.observer/filing/0001564590-21-036895.json
- Plain text: https://secwatch.observer/filing/0001564590-21-036895.txt

## Key facts
- Executive change
  Nathalie Adda departed as Senior Vice President, Chief Medical Officer at ENANTA PHARMACEUTICALS INC.
  - Action: announced her retirement
  - Role: Senior Vice President, Chief Medical Officer
  source text: On July 14, 2021, Nathalie Adda, M.D., Senior Vice President, Chief Medical Officer of Enanta Pharmaceuticals, Inc. (“Enanta”) announced her retirement effective February 28, 2022 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1177648/000156459021036895/0001564590-21-036895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.